Case Report
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 6, 2020; 8(23): 6048-6055
Published online Dec 6, 2020. doi: 10.12998/wjcc.v8.i23.6048
Roxadustat for treatment of erythropoietin-hyporesponsive anemia in a hemodialysis patient: A case report
Wei-Hong Yu, Xie-Jia Li, Fang Yuan
Wei-Hong Yu, Xie-Jia Li, Fang Yuan, Department of Nephrology, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China
Author contributions: Yuan F designed the study; Li XJ and Yu WH collected the patient’s clinical data and contributed to drafting the manuscript; and all authors issued final approval for this version to be submitted.
Supported by the National Natural Science Foundation of China, No. 81770730; and the Hunan Provincial Natural Science Fund, No. 2017JJ2352.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fang Yuan, MD, PhD, Chief Doctor, Department of Nephrology, The Second Xiangya Hospital of Central South University, No. 139 Renmin Road, Changsha 410011, Hunan Province, China. yuanfang@csu.edu.cn
Received: May 28, 2020
Peer-review started: May 28, 2020
First decision: September 13, 2020
Revised: September 26, 2020
Accepted: October 19, 2020
Article in press: October 19, 2020
Published online: December 6, 2020
Processing time: 189 Days and 19.2 Hours
Core Tip

Core Tip: We present a case of refractory erythropoiesis-stimulating agent hyporesponsiveness-related anemia in which oral roxadustat increased and maintained hemoglobin. Roxadustat may be a useful optional treatment for anemia in patients with chronic kidney disease. Future clinical trials are needed to assess potential problems with hypoxia-inducible factor prolyl hydroxylase inhibitors.